Simeprevir
Simeprevir is a macrocyclic peptidomimetic inhibitor of the hepatitis C virus NS3/4A serine protease, used for the treatment of chronic hepatitis C virus (HCV) genotype 1 and 4 infection in combination with other antiviral agents. By competitively binding the NS3/4A protease active site, it blocks viral polyprotein processing and inhibits HCV replication. It achieves high sustained virologic response rates when combined with sofosbuvir or pegylated interferon plus ribavirin.
분자량
749.9000 g/mol
LogP
4.80
TPSA
194.00 Ų
리핀스키 5의 법칙
통과
치료 영역
작용 기전
Inhibits the NS3/4A serine protease of hepatitis C virus, blocking the processing of the viral polyprotein essential for replication.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits the NS3/4A serine protease of hepatitis C virus, blocking the processing of the viral polyprotein essential for replication.
2D 구조
Cite this structure
Embed this structure
SMILES
COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6CC6)C[C@H]5/C=C\CCCCN(C)C(=O)[C@@H]4C3)cc(-c3nc(C(C)C)cs3)nc2c1C
InChI
InChI=1S/C38H47N5O7S2/c1-21(2)30-20-51-35(40-30)29-18-32(26-13-14-31(49-5)22(3)33(26)39-29)50-24-16-27-28(17-24)36(45)43(4)15-9-7-6-8-10-23-19-38(23,41-34(27)44)37(46)42-52(47,48)25-11-12-25/h8,10,13-14,18,20-21,23-25,27-28H,6-7,9,11-12,15-17,19H2,1-5H3,(H,41,44)(H,42,46)/b10-8-/t23-,24-,27-,28-,38-/m1/s1
Molecular Formula
C38H47N5O7S2
HBD / HBA
2 / 10
회전 가능 결합
8
무거운 원자
52
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
자주 묻는 질문
Simeprevir is a macrocyclic peptidomimetic inhibitor of the hepatitis C virus NS3/4A serine protease, used for the treatment of chronic hepatitis C virus (HCV) genotype 1 and 4 infection in combination with other antiviral agents. By competitively binding the NS3/4A protease active site, it blocks viral polyprotein processing and inhibits HCV replication. It achieves high sustained virologic response rates when combined with sofosbuvir or pegylated interferon plus ribavirin.
Inhibits the NS3/4A serine protease of hepatitis C virus, blocking the processing of the viral polyprotein essential for replication.
Yes, Simeprevir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL501849. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 24873435. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="simeprevir"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/simeprevir/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/simeprevir/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/simeprevir/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="simeprevir"></drugfyi-drug>